Skip to content

Correlation between the level of serum biochemical markers and recent cardiac events

Early diagnosis and integrated Chinese and Western therapy for coronary vulnerable plaque (EDITIMI-CVP)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ECH-08000086
Enrollment
Unknown
Registered
2008-04-16
Start date
2006-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

Patients with coronary atherosclerosis:Test serum biochemical markers in venous blood
follow up for 3 years
and divide the patients into cohort of patients with cardiac events and cohort of patients without cardiac events

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Males or non-pregnant females; aged between 18 and 80 years old; 2. Diagnosed with unstable angina pectoris (initial onset, accelerated angina and angina at rest); 3. Coronary angiography shows that stenosis of the main branches (left main coronary artery, anterior descending branch, circumflex branch and right coronary artery) of non-PCI coronary artery >20%; localized lesions and at least stenosis of one branch =2.25mm; 5. Willing to be followed up and evaluated; 6. Sign the informed content forms approved by ethnics committee.

Exclusion criteria

Exclusion criteria: 1. Acute myocardial infarction with ST elevation 2. Combined with valves diseases 3. Combined with cardiomyopaty 4. Re-stenosis after stent placement; 5. Patients with coronary artery bypass grafting; 6. Complete occlusion of vessels confirmed by coronary angiography (TIMI Grade 0); 7. Left ventricular ejection fraction 2.5mg/dl in male and >2.0mg/dl in female; 11. Hepatic insufficiency, baseline for liver enzyme >triple of normal value; 12. Organic damage of central nervous system within 3 months; 13. Patients with heart transplantation; 14. Advanced tumors; 15. Patients with multiple organ failure; 16. Patients whose expected life <3 years; 17. Patients participating in other clinical trials without completing primary outcomes within 30 days before the study; 18. Patients with poor compliance, failing to complete the follow-ups or the study.

Design outcomes

Primary

MeasureTime frame
Biochemical markers;

Countries

China

Contacts

Public ContactShuzheng Lv
shuzheng@medmail.com.cn+86 010 64456981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026